Imagenetix Announces Interim Award in Arbitration with TriPharma
Posted on September 19, 2011 at 16:33 PM EDT
SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Imagenetix, Inc. (OTCBB: IAGX) announced today that it received an adverse decision in an interim arbitration award arising out of its pending dispute with former distributor TriPharma, LLC and its principal, Evan Dameshek. The arbitration is pending before a private arbitrator and is conducted under the rules of JAMS (Judicial Arbitration and Mediation Services) in San Diego, California. The interim award against the Company and its President, William Spencer, is for approximately $2.2 million plus as yet not determined legal fees and interest. "We obviously are not happy with the outcome of this case and are considering our legal options," said Mr. Spencer.
Imagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis. Imagenetix develops and formulates propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Celadrin®. Please visit, www.celadrin.com or www.imagenetix.net.
SOURCE Imagenetix, Inc.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here